Plenadren®, an orphan drug from DuoCort Pharma for treating adrenal insufficiency, granted marketing authorization in the EUPress Release Nov 07, 2011 16:00 EST
DuoCort AB has reached an agreement with pharmaceuticals company ViroPharma Incorporated to sell its subsidiary DuoCort Pharma AB with Plenadren®, a new treatment for adrenal insufficiency, also known as Addison’s disease. Plenadren was developed in house by DuoCort Pharma AB. The total value of the deal is over SEK 1 billion.
LIDDS new local treatment of prostate cancer shows a clear local antiandrogen response and is well tolerated. The Swedish pharmaceutical company presented interim data from its phase IIa trial at the 26th Annual Congress of the European Association of Urology (EAU) in Vienna this weekend.